Brief: Keros Therapeutics Board Undertaking Formal Review Process To Evaluate Strategic Alternatives
19/05/2025 13:18
May 19 (Reuters) - Keros Therapeutics Inc KROS.O: KEROS THERAPEUTICS INC - BOARD UNDERTAKING FORMAL REVIEW PROCESS TO EVALUATE STRATEGIC ALTERNATIVES Source text: ID:nGNX7JGtCR Further company coverage: KROS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Keros Therapeutics
See all newsBrief: Keros Therapeutics May Offer Up To $350 Million Of Securities - SEC Filing
Keros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Keros Therapeutics Q2 net loss narrows on lower expenses
Brief: Keros Therapeutics - Keith Regnante Resigns As CFO
Keros Therapeutics posts Q1 net loss as license revenue drops